Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Minority Interest (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Minority Interest for 4 consecutive years, with $36.3 million as the latest value for Q4 2025.

  • Quarterly Minority Interest rose 3.33% to $36.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $36.3 million through Dec 2025, up 3.33% year-over-year, with the annual reading at $36.3 million for FY2025, 3.33% up from the prior year.
  • Minority Interest for Q4 2025 was $36.3 million at Gyre Therapeutics, up from $35.5 million in the prior quarter.
  • The five-year high for Minority Interest was $37.4 million in Q2 2025, with the low at $29.7 million in Q4 2022.
  • Average Minority Interest over 4 years is $34.0 million, with a median of $35.2 million recorded in 2024.
  • The sharpest move saw Minority Interest grew 0.28% in 2023, then grew 17.82% in 2024.
  • Over 4 years, Minority Interest stood at $29.7 million in 2022, then rose by 0.28% to $29.8 million in 2023, then grew by 17.82% to $35.1 million in 2024, then increased by 3.33% to $36.3 million in 2025.
  • According to Business Quant data, Minority Interest over the past three periods came in at $36.3 million, $35.5 million, and $37.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.